# A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

> **NCT06462404** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 22 (actual)

## Conditions studied

- Narcolepsy Type 1 (NT1)

## Interventions

- **DRUG:** E2086
- **DRUG:** E2086 Placebo
- **DRUG:** Active Comparator
- **DRUG:** Active Comparator Placebo

## Key facts

- **NCT ID:** NCT06462404
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-20
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462404, "A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06462404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*